FORMULATION AND EVALUATION OF SODIUM ALGINATE BEADS AND SUSTAINED-RELEASE PELLETS OF RABEPRAZOLE SODIUM
Universal Journal of Pharmaceutical Research · 15.11.2026
DOI: 10.22270/ujpr.v11i5.1664 ↗Kurz gefasst
Fachartikel in der Zeitschrift Universal Journal of Pharmaceutical Research, online erschienen am 15.11.2026. Verfasst von S. Madhankumar und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Rabeprazole sodium is a proton pump inhibitor that degrades rapidly in acidic media. Prolonged-release oral forms must therefore limit its exposure to gastric acid while controlling its release in the intestine.
Objective
To develop and evaluate two independent multiparticulate systems of rabeprazole sodium, namely calcium alginate beads and Eudragit RS100-coated sustained-release pellets.
Methods
Calcium alginate beads were generated by ionotropic gelation using a two-factor, three-level factorial arrangement comprising sodium alginate at 2.0–3.0% w/v and calcium chloride at 1.0–2.0% w/v. A separate pellet series was manufactured by powder layering onto sugar spheres and subsequent application of Eudragit RS100 coatings containing triethyl citrate at 0–20% of the polymer mass. Characterization encompassed manufacturing recovery, drug incorporation, particle attributes and UV-derived apparent release. The selected pellet formulation underwent additional release-model fitting, scanning electron microscopy and storage assessment.
Results
Increasing the concentrations of sodium alginate, and calcium chloride increased bead yield (82.4–91.0%), entrapment efficiency (78.6–91.6%) and size, and decreased swelling and drug release at 8 h (from 91.8% to 73.5%). Formulation B5 showed a balanced profile with an entrapment efficiency of 87.6±1.0%. In the pellet series, increasing the triethyl citrate level progressively retarded drug release at 12 h, from 96.8% (F1) to 76.5% (F5). The drug content and 12 h release of F5 changed by less than two percentage points after 6th months of accelerated and 12th months of long-term storage.
Conclusion
Triethyl citrate concentration was a critical variable governing drug release from Eudragit RS100-coated rabeprazole sodium pellets. Formulation F5 met all predefined quality and release criteria and remained stable during storage, identifying it as a promising sustained-release multiparticulate candidate for further development. Peer Review History: Received 25 July 2026; Reviewed 3 September 2026; Accepted 8 October; Available online 15 November 2026 Academic Editor: Dr. Ali Abdullah Al-yahawi, Al-Razi university, Department of Pharmacy, Yemen, alyahawipharm@yahoo.com Reviewers: Eyassu Mathewos, Department of Nursing, College of Medicine and Health Sciences, Wachamo University, Durame Campus, Durame, Ethiopia, eyumathi@gmail.com Dr. Julie Ann S. Ng, Blk 18 Lot 6 Grandville 3 Subdivision Mansilingan, Bacolod City, Philippines. julieann_ng@yahoo.com
Zitieren
APA
Madhankumar, S., Mariyappan, G., Karthi, J., & Murugan, P. (2026). FORMULATION AND EVALUATION OF SODIUM ALGINATE BEADS AND SUSTAINED-RELEASE PELLETS OF RABEPRAZOLE SODIUM. Universal Journal of Pharmaceutical Research. https://doi.org/10.22270/ujpr.v11i5.1664
Vancouver
Madhankumar S, Mariyappan G, Karthi J, Murugan P. FORMULATION AND EVALUATION OF SODIUM ALGINATE BEADS AND SUSTAINED-RELEASE PELLETS OF RABEPRAZOLE SODIUM. Universal Journal of Pharmaceutical Research. 2026. doi:10.22270/ujpr.v11i5.1664
BibTeX
@article{Madhankumar2026,
author = {Madhankumar, S. and Mariyappan, G. and Karthi, J. and Murugan, Prakash},
title = {FORMULATION AND EVALUATION OF SODIUM ALGINATE BEADS AND SUSTAINED-RELEASE PELLETS OF RABEPRAZOLE SODIUM},
journal = {Universal Journal of Pharmaceutical Research},
year = {2026},
doi = {10.22270/ujpr.v11i5.1664}
}
EUVIMED